EUVIMEDEUVIMED entdecken
Crossref

A proliferative-luminal phenotype predicts trastuzumab deruxtecan sensitivity independent of HER2 expression in ER-positive breast cancer

R. El Botty, E. Montaudon, J. Marsolier, G. Jouault, J. Sauge, H. Darrien, L. Courtois, L. Grynszpan, C. Guerin, F. Guillonneau, A. Patsouris, P. Poullet und 5 weitere

European Journal of Cancer · 2026-11 · 248 · 117477

DOI: 10.1016/j.ejca.2026.117477 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von R. El Botty und 16 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Botty, R. E., Montaudon, E., Marsolier, J., Jouault, G., Sauge, J., Darrien, H., Courtois, L., Grynszpan, L., Guerin, C., Guillonneau, F., Patsouris, A., Poullet, P., Bieche, I., Coussy, F., Cabel, L., Vallot, C., & Marangoni, E. (2026). A proliferative-luminal phenotype predicts trastuzumab deruxtecan sensitivity independent of HER2 expression in ER-positive breast cancer. European Journal of Cancer, 248, 117477. https://doi.org/10.1016/j.ejca.2026.117477

Vancouver

Botty RE, Montaudon E, Marsolier J, Jouault G, Sauge J, Darrien H, et al. A proliferative-luminal phenotype predicts trastuzumab deruxtecan sensitivity independent of HER2 expression in ER-positive breast cancer. European Journal of Cancer. 2026;248:117477. doi:10.1016/j.ejca.2026.117477

BibTeX
@article{Botty2026,
  author = {Botty, R. El and Montaudon, E. and Marsolier, J. and Jouault, G. and Sauge, J. and Darrien, H. and Courtois, L. and Grynszpan, L. and Guerin, C. and Guillonneau, F. and Patsouris, A. and Poullet, P. and Bieche, I. and Coussy, F. and Cabel, L. and Vallot, C. and Marangoni, E.},
  title = {A proliferative-luminal phenotype predicts trastuzumab deruxtecan sensitivity independent of HER2 expression in ER-positive breast cancer},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {248},
  pages = {117477},
  doi = {10.1016/j.ejca.2026.117477}
}
Kostenlos starten →